[Form 4] Helix Acquisition Corp. II Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. director Jake Bauer reported acquisition of a stock option on 08/26/2025. The Form 4 discloses a grant (transaction code A) of a Stock Option (Right to Buy) covering 138,193 underlying shares of Common Stock with an exercise price of $9.59. The form shows 138,193 derivative securities beneficially owned following the transaction and lists the option as direct ownership. The table includes a date field of 08/25/2035 in the exercisable/expiration column. The filing includes a vesting description: vesting is tied to an S-8 filing and then monthly vesting over a 48-month schedule measured from an April 25, 2025 vesting commencement date. The Form 4 was signed by an attorney-in-fact on 08/28/2025.

Positive

• Director alignment through equity: a sizeable option grant (138,193 shares) aligns the reporting person's interests with shareholders
• Clear vesting schedule: vesting terms are explicitly described and tied to an S-8 filing with monthly vesting over 48 months

Negative

• Limited exercisability/expiration clarity: the form lists 08/25/2035 in the exercisable/expiration column but does not clarify full exercisability timing
• No dollar-value disclosure: the filing does not include grant fair-value or other economic terms beyond exercise price

Insights

Securities Analyst

TL;DR: Routine director equity grant: large option award aligns incentive but contains standard multi-year vesting tied to an S-8 registration.

The filing documents a single derivative acquisition by a director under transaction code A, indicating an option grant for 138,193 shares at $9.59 per share. The option is recorded as directly beneficially owned after the grant. The vesting mechanics are explicit: an initial fractional vesting upon effectiveness of an S-8 registration based on months elapsed since April 25, 2025, then monthly vesting over a 48-month schedule until fully vested. The exercisable/expiration date field shows 08/25/2035; the form does not provide additional performance conditions, cash payments, or explicit grant fair-value figures. For investors, this filing is a standard disclosure of insider compensation rather than an operational or financial performance signal.

Corporate Governance Expert

TL;DR: Standard governance disclosure: director received an equity-based award with time-based vesting tied to an S-8 filing.

The Form 4 is consistent with customary director compensation through equity incentives. It specifies direct beneficial ownership post-grant and a clear vesting formula tied to the S-8 registration date and a 48-month monthly vesting schedule measured from April 25, 2025. The filing does not indicate acceleration clauses, change-in-control terms, or departures from typical equity award governance. The document is informational for compliance with Section 16 reporting obligations and does not by itself indicate any governance irregularity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauer Jake

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		138,193		(1)	08/25/2035	Common Stock	138,193	$0	138,193	D

Explanation of Responses:

1. A fraction of the shares underlying such option equal to (x) the number of full months between April 25, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jake Bauer (director) report on Form 4 for BBOT?

The Form 4 reports an acquisition (transaction code A) of a Stock Option to purchase 138,193 shares at an exercise price of $9.59 on 08/26/2025.

How many shares does the reported option cover and who owns them?

The option covers 138,193 underlying shares of Common Stock and is reported as direct beneficial ownership following the transaction.

What are the vesting terms for the option reported on Form 4?

Vesting is tied to an S-8 registration: a fraction vests on the S-8 Filing Date based on months elapsed since April 25, 2025, then 1/48th of the shares vest each month thereafter until fully vested over 48 months, subject to continuous service.

What is the exercise price and transaction date disclosed?

The exercise price is $9.59 per share and the transaction date is 08/26/2025.

Who signed the Form 4 and when was it signed?

The Form 4 shows a signature by /s/ Aaron Chan, Attorney-in-Fact dated 08/28/2025.